A study testing whether a GLP-1 medicine, semaglutide, can help people with atrial fibrillation lose weight.

Recruiting now. Registry record last updated November 14, 2025.

Who can join: Adults 18 to 75, have obesity or are overweight, BMI 30+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3.2 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor University of ChicagoDrug semaglutideClass GLP-1 RASites 2 USEnrollment target 200

What this study is for

Primary condition: Overweight or Obesity. Also studied in: Atrial Fibrillation.

Full scientific study title: Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation.

Who can join

Age18 to 75SexAnyBMI30 or higher

Adults 18 to 75, have obesity or are overweight, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age 18-75 years
BMI greater than or equal to 30 kg/m2
Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)
Ability to provide informed consent before any trial-related activities.
Patients with type 2 diabetes mellitus (T2DM) will be included:

Key exclusion criteria

Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening
Current antiobesity medication use or use within the last 90 days prior to screening
A self-reported change in body weight of \> 5 kg (11 lb.) within 30 days before screening
History of bariatric surgery
History of type I diabetes mellitus

Where this trial is enrolling

This trial has 2 sites across 2 states. Contact a site coordinator directly to start screening.

Find a site near you

Arizona1 site

The University of Arizona College of Medicine- Phoenix
Phoenix, Arizona
Roderick Tung, MD602-521-3090rodericktung@arizona.edu

Illinois1 site

University of Chicago
Chicago, Illinois
Silvana Pannain, MD773-702-3275spannain@bsd.uchicago.edu

Follow this trial

We email you if NCT06499857 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: April 14, 2025. Expected completion: June 2028. Last updated on ClinicalTrials.gov: November 14, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.